publication date: May. 30, 2014


DePinho’s Letter to the AAUP

Responding to an inquiry by the American Association of University Professors, MD Anderson Cancer Center President Ronald DePinho said his critics are incorrect in asserting that his administration gave no formal explanation for denying tenure renewal to two faculty members.

The full text of the letter, addressed to Gregory Scholtz, AAUP associate secretary and director of the Department of Academic Freedom, Tenure and Governance, follows:

Dear Dr. Scholtz:

This letter is in response to your May 13, 2014 correspondence concerning your interest in the non-renewal of appointments for Dr. Kapil Mehta and Dr. Zhengxin Wang, as well as the protection of academic freedom and due process for faculty at The University of Texas
MD Anderson Cancer Center.

You wrote that the information provided to your organization regarding Drs. Mehta and Wang has come primarily from those individuals, and you also acknowledged that MD Anderson may have additional information that would contribute to your understanding of these matters. We very much appreciate your invitation to comment on this matter and value the opportunity to provide additional information on our processes.

Regrettably, we do not believe you have all of the relevant information pertaining to these matters.

While it is MD Anderson’s practice to avoid communications with outside parties related to faculty personnel matters, we appreciate the opportunity to respond.

We are providing the information below so that the American Association of University Professors may better understand MD Anderson’s policies and practices that honor, protect and enhance the professional careers of our esteemed faculty at our comprehensive cancer center.

Continue reading 40-22 DePinho Explains Tenure Decision, Professors Dispute Key Details 2

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.